In the present study, the cytogenetic effects of the platinum based anti-tumour drug heptaplatin were analysed by measuring chromosomal aberrations and the mitotic index, in bone marrow cells of SWR/J mice. A single 5, 10 or 12.5 mg/kg body weight (b.wt) intraperitoneal dose of heptaplatin was administered to the experimental animal groups while the control group were injected i.p. with normal saline (0.4 ml). Animals from all the groups were sacrificed at sampling times of 24, 48, and 72 h and their bone marrow cells were scrutinized for cytogenetic damage. It was observed that with the three disparate doses of heptaplatin significantly high levels of chromosomal aberration were seen in animals in the initial 24 h, compared to the normal group but these gradually reduced after 48 and 72 h. A similar trend was observed in aberrations with G, without G and in the mitotic index for all three dosages levels. The present study demonstrates that a single i.p. administration of 5, 10 or 12.5 mg/kg b.wt. of heptaplatin significantly reduces the mitotic indices and highly significantly induces chromosomal aberrations (both numerically and structurally) in proliferative bone marrow cells of SWR/J mice.